CMS’ Phurrough Stresses Need For Continuous Data Collection
This article was originally published in The Gray Sheet
Executive Summary
Citing safety issues that might only materialize after "technology is diffused to a larger population," Steve Phurrough, Director of the CMS Coverage and Analysis Group, urges device makers to continue to gather critical data on their products long after they receive FDA approval and enter the commercial market
You may also be interested in...
Device Makers Cite Special Concerns With Comparative Effectiveness
Comparative effectiveness research, where evidence supporting an established medical therapy is stacked up against that of up-and-coming approaches, is a small but growing element of the U.S. government's strategy for assessing health care
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.